Open AccessApplying gene‐editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer’s disease
Author(s) -
Schrauben Michael,
Dempster Emma,
Lun Katie
Publication year - 2020
Publication title -
brain pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.986
H-Index - 132
eISSN - 1750-3639
pISSN - 1015-6305
DOI - 10.1111/bpa.12881
Subject(s) - epigenetics , crispr , disease , computational biology , biology , chromatin , epigenesis , gene , genome editing , genetics , regulation of gene expression , genome , gene expression , neuroscience , dna methylation , medicine , pathology
Recent studies have highlighted a potential role of genetic and epigenetic variation in the development of Alzheimer’s disease. Application of the CRISPR‐Cas genome‐editing platform has enabled investigation of the functional impact that Alzheimer’s disease‐associated gene mutations have on gene expression. Moreover, recent advances in the technology have led to the generation of CRISPR‐Cas–based tools that allow for high‐throughput interrogation of different risk variants to elucidate the interplay between genomic regulatory features, epigenetic modifications, and chromatin structure. In this review, we examine the various iterations of the CRISPR‐Cas system and their potential application for exploring the complex interactions and disruptions in gene regulatory circuits that contribute to Alzheimer’s disease.